linjc16/ctgov huggingface dataset:
Mindreading in Adults With Autism Spectrum Disorder

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the ability of reading emotions by the Eyes task in adults with ASD, and examine the gazing pattern and frontal activation during the task. We plan to recruit 50 adults with ASD and 50 typically-developing adults. Eye-tracking and frontal activation (measured by functional near-infrared spectroscopy) will be examined during the Eyes task.

Detailed Description
-----------------
Autism spectrum disorder (ASD) is a clinical syndrome characterized by mindreading deficits, or Theory of Mind deficits. The Reading the Mind in the Eyes task (abbreviated as the Eyes task) was developed to assess the mindreading deficits as a hallmark of social deficits of ASD. This study aims to investigate the ability of reading emotions by the Eyes task in adults with ASD, and examine the gazing pattern and frontal activation during the task. We plan to recruit 50 adults with ASD and 50 typically-developing adults. All the participants will complete clinical measures and the Eyes task. Eye-tracking and frontal activation (measured by functional near-infrared spectroscopy) will be examined during the Eyes task.

Official Title
-----------------
Mindreading in Adults With Autism Spectrum Disorder

Conditions
-----------------
Autism Spectrum Disorder

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult aged between 20 and 50 years who had a diagnosis of ASD based on DSM-5. Had a full-scale IQ > 70 on WAIS-IV. Exclusion Criteria: A history of major mental illness (e.g., bipolar affective disorder, schizophrenia) or neurological diseases. Visual impairment and that would preclude participation.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ASD Group<br>Autism spectrum disorder participants, no intervention | Other: no intervention<br>* no intervention<br>|
| TD Group<br>Typically developmental controls,no intervention | Other: no intervention<br>* no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| eye tracking indicators | eye tracking indicators | 30 min |
Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain

Study Overview
=================
Brief Summary
-----------------
Functional magnetic resonance imaging in women with chronic pelvic pain using arterial spin labelling, functional connectivity, diffusion tensor imaging and magnetic resonance spectroscopy.

Detailed Description
-----------------
Multimodal magnetic resonance neuroimaging will be utilised. Arterial spin labelling is tightly coupled with cerebral metabolism and can be used as a marker of neural activity. Resting state magnetic resonance imaging which measures synchronous activity across the brain, allows detection of functional connectivity of intrinsic brain network. Diffusion tensor imaging detects the anisotropic water diffusion in axonal fibres can provide information on connectivity and fibre tracts. Magnetic resonance spectroscopy would enable the levels of neurotransmitter to be elucidated.

Official Title
-----------------
Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain

Conditions
-----------------
Pelvis Pain Chronic, Endometriosis of Uterus

Intervention / Treatment
-----------------
* Other: Functional magnetic resonance imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic pelvic pain Endometriosis Exclusion Criteria: Contraindication to magnetic resonance imaging

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Magnetic resonance imaging<br>Functional magnetic resonance imaging using arterial spin labelling, functional connectivity, diffusion tensor imaging, magnetic resonance spectroscopy to evaluate women with chronic pelvic pain and/ or endometriosis | Other: Functional magnetic resonance imaging<br>* 3 Tesla magnetic resonance imaging<br>* Other names: FMRI;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with increase in insula anterior cingulate cortex signal on magnetic resonance imaging | Magnetic resonance imaging using arterial spin labelling, functional connectivity, diffusion tensor imaging, magnetic resonance imaging | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects in psychological testing with increased anxiety, depression and pain catastrophizing scores | Anxiety, depression and pain catastrophizing scales used for psychological testing | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic pelvic pain, Endometriosis
Left Atrial Volume as Predictor for Arrhythmic Events and CRT Response

Study Overview
=================
Brief Summary
-----------------
Left atrial volume role for CRT response and for arrhythmic events (VT/VF/AT/AF) onset

Official Title
-----------------
Left Atrial Volume as Predictor for Arrhythmic Events and CRT Response

Conditions
-----------------
Left Atrial Volume

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with left ventricular ejection fraction ≤ 35%, II, III or IV NYHA Class, even if optimal medical therapy. Patients with standard indication to CRT according current guideline, sinus rhythm at implantation, LBBB and QRS duration >= 120 ms Patients who will undergo to a new CRT-defibrillator system implantation Patients who are able to understand and sign the informed consent Patients who are able to attend all required follow-up visits at the study centerfor 24 months Exclusion Criteria: Age < 18 years Women who are pregnant or who are planning to become pregnant Patients with permanent Atrial Fibrillation or persistent Atrial Fibrillation in the 90 days preceding the implantation Patients with organic mitral valve disease Patients with prosthetic heart valves Patients who will undergo to upgrading from other devices (PM or ICD) to CRT, heart transplantation, patients with CRT devices

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac remodelling | Evaluation of function and volume of left atrium (by means of echocardiographic measures) in terms of cardiac remodelling (at least 15% reduction in LVESV). | 6 months | 
| CRT Predictor Index | Identification of left atrial index predicting CRT response | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical benefit | Left atrial volume/function in terms of clinical benefit Clinical Composite Score evaluation QoL evaluation | 12 months | 
| Cardiac remodelling | Left atrial volume/function in terms of cardiac remodelling LVEF LVESV/LVEF | 6 months | 
| Atrial arrhythmias | Left atrial volume/function role in terms of: atrial arrhythmias onset Atrial arrhythmias burden | 24 months | 
| Ventricular arrhythmias | Left atrial volume/function in terms of: ventricular arrhythmias onset ventricular arrhythmias burden | 24 months |
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.

Official Title
-----------------
Genetic Testing of Noonan Subjects Previously Treated With Norditropin® in the GHNOO-1658 Trial

Conditions
-----------------
Genetic Disorder, Noonan Syndrome

Intervention / Treatment
-----------------
* Drug: somatropin
* Drug: somatropin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in the GHNOO-1658 trial Subject has completed genetic testing of PTPN11 mutation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low dose 33 mcg/kg/day<br> | Drug: somatropin<br>* Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.<br>|
| Experimental: High dose 66 mcg/kg/day<br> | Drug: somatropin<br>* Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in height SDS (Standard Deviation Score) (referenced to normal population) |  | From baseline until final height is reached | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Final height SDS (referenced to normal population) |  | From baseline until final height is reached | 
| Final height SDS (referenced to Noonan population) |  | From baseline until final height is reached | 
| Change in height SDS (referenced to Noonan population) |  | From baseline until final height is reached | 
| Number of subjects with final height SDS above - 2SDS (reference to normal population) |  | When final height is reached | 
| Proportion of subjects with final height SDS above - 2SDS (reference to normal population) |  | When final height is reached | 
| Adverse events |  | From baseline until final height is reached |
Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to generate early US feasibility data of the CardiAQ™ Transcatheter Mitral Valve Implant System. The study will enroll patients with moderate to severe mitral valve regurgitation who are considered high risk for mortality and morbidity from conventional open-heart surgery.

Detailed Description
-----------------
Early feasibility study - multi-center, prospective, single-arm, and non-randomized study without concurrent or historical controls. The primary objective of the study is to generate early feasibility data for the CardiAQ™ Transcatheter Mitral Valve Implant System with the Transfemoral and Transapical Delivery Systems for the treatment of moderate to severe mitral valve regurgitation in patients who are considered high risk for mortality and morbidity from conventional open-heart surgery. The secondary objectives of the study are to evaluate the long-term safety of the device and the effects of the device on performance, functional, quality of life parameters, and technical, device, procedural, and individual patient successes. The study is to be performed at a maximum of 5 investigational sites in the US.

Official Title
-----------------
Early Feasibility Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transfemoral and Transapical Delivery Systems)

Conditions
-----------------
Mitral Insufficiency, Heart Valve Disease, Cardiovascular Disease, Heart Disease

Intervention / Treatment
-----------------
* Device: CardiAQ TMVI System (Transapical & Transfemoral DS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: NYHA Classification ≥ III Left Ventricular Ejection Fraction ≥ 30% Mitral Regurgitation ≥ Grade 3+ Subject meets anatomical and eligibility criteria for the investigational device Exclusion Criteria: See Protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CardiAQ TMVI System (Transapical & Transfemoral DS)<br>CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System | Device: CardiAQ TMVI System (Transapical & Transfemoral DS)<br>* CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite Major Adverse Event Rate |  | 30-Day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transcatheter Mitral Valve Replacement, Mitral Regurgitation, Mitral Insufficiency, Transapical, Transfemoral
Can Japanese Traditional Foods Lower Blood Pressure in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether traditional japanese diet blood pressure in healthy volunteers.

Detailed Description
-----------------
Japanese traditional diet contains considerably more nitrate/nitrite than the European foods. 80% of dietary nitrate originates from vegetables. Green leafy vegetables, especially spinach, salad and seaweed are rich in nitrates. Other vegetables contain nitrate at lower concentrations, but because they are consumed in greater quantity, they may contribute more nitrate and thus nitrite from the diet. Nitrate/nitrite is attributed multiple health benefits. Japanese people have an exceptional longevity and the lowest rate of heart diseases. On the other hand, gastric cancer rate is high too. Nitrate/nitrite is strongly correlated with these phenomena. Is this high nitrate consumption protective or damaging? Understanding dietary nitrite and nitrate consumption and its metabolism therefore becomes very important. Aim: To compare conversion of nitrate to nitrite in Japanese people, measured in blood and in saliva during consumption of traditional Japanese foods vs European diet.

Official Title
-----------------
Dietary Nitrate in Japanese Traditional Foods Lowers Diastolic Blood Pressure in Healthy Volunteers.

Conditions
-----------------
Blood Pressure

Intervention / Treatment
-----------------
* Dietary Supplement: traditional Japanese diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteers Exclusion Criteria: high/low blood pressure

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure |  |  |
Single Anastomosis Sleeve Jejunal (SAS-J) Bypass

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the efficacy of single anastomoses sleeve jejunal bypass as a treatment for morbid obesity

Detailed Description
-----------------
in this study the investigators aim to test a new technique ( single anastomoses sleeve jejunal as a treatment for morbid obesity Which is a modification of Single anastomoses sleeve ileal bypass with short biliary limb ( about one third of the small intestine from the Duodeno-jejunal junction

Official Title
-----------------
Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A Treatment for Morbid Obesity

Conditions
-----------------
Morbid Obesity

Intervention / Treatment
-----------------
* Procedure: Single Anastomosis Sleeve Jejunal (SAS-J) Bypass


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: obese patients with BMI more than 40 patients fit for laparoscopic surgery give approval to share in the study Exclusion Criteria: patients refused to share in the study patients unfit for surgery patients aged less than 18 and older than 50 patients with BMI less than 50 patient with previous upper abdominal surgery either for obesity or other diseases patients with preoperative GERD clinically or by investigation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single Anastomosis Sleeve Jejunal (SAS-J) Bypass<br>Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid | Procedure: Single Anastomosis Sleeve Jejunal (SAS-J) Bypass<br>* Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| operative time | the operative time from skin incision to skin closure | the 1st 24 hours | 
| intraoperative complications | intraoperative complications like bleeding, other organs injuries | the 1st 24 hours | 
| the postoperative weight loss | the percentage of weight loss from total excess body weight | 12 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effect on metabolic syndrome if present | effect on blood sugar level, blood pressure and blood cholesterol level | 12 months |
Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Study Overview
=================
Brief Summary
-----------------
Avastin is a novel antiangiogenic agent that has recently been shown to improve response rates and survival of patients with advanced nonsquamous non-small cell lung cancer when added to front-line carboplatin/paclitaxel chemotherapy, and is now being routinely incorporated into the treatment of these patients. Alimta is a recently approved chemotherapeutic that has shown activity against non-small cell lung cancer when given alone and in combination with carboplatin, has a favorable toxicity profile andrequires only a brief (10 minute) infusion time. Therefore we propose to study the combination of Avasin, Alimta, and Carboplatin administered as front-line therapy to patients with advanced nonsquamous non-small cell lung cancer.

Official Title
-----------------
Phase II Trial of Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Conditions
-----------------
Untreated Advanced Non-Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: Avastin, Alimta


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: I am 18 years of age or older. I have advanced non-small lung cancer. I have not had any major surgical procedures within 28 days prior to my starting treatment. I have high blood pressure that is controlled. I am not on heparin, coumadin or lovonox for treatment of medical conditions. I do not have serious wound healing problems. I have not received any previous treatment, except radiation therapy for my disease. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Avastin, Alimta|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Urotensin II in Chronic Kidney Diseases and Kidney Transplants

Study Overview
=================
Brief Summary
-----------------
The investigators are planning to study the serum level of Urotensin II in chronic kidney disease patients, kidney transplants, and healthy controls.

Detailed Description
-----------------
The investigators will determine the urotensin II levels in Chronic kidney disease patients, kidney transplants, and healthy controls.

Official Title
-----------------
Urotensin II in Chronic Kidney Diseases

Conditions
-----------------
Chronic Renal Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age more than 18 Exclusion Criteria: Inability to give a written consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Healthy controls | |
| Chronic kidney disease-1<br>Chronic kidney disease not taking dialysis treatment | |
| Kidney Transplant<br>Kidney transplants | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum Urotensin II(UII)level | We tried to compare UII level in normal, chronic kidney disease and kidney transplant patients group | at enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Urotensin II,Chronic renal disease